NASDAQ:SPPI Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis → This could mean the end of the U.S dollar… (From Colonial Metals) (Ad) Free SPPI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.03▼$1.0350-Day Range$0.94▼$1.0352-Week Range$0.32▼$1.57VolumeN/AAverage Volume1.93 million shsMarket Capitalization$211.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI)Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Read More Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. SPPI Stock News HeadlinesMay 23 at 7:00 AM | globenewswire.comPneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 ConferenceMay 2, 2024 | globenewswire.comPneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024February 21, 2024 | markets.businessinsider.comAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTFebruary 21, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming DeadlineFebruary 8, 2024 | markets.businessinsider.comLost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyFebruary 5, 2024 | markets.businessinsider.comAssertio Holdings, Inc. (NASDAQ: ASRT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class ActionFebruary 1, 2024 | stockhouse.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)February 1, 2024 | markets.businessinsider.comCLASS ACTION NOTICE: Berger Montague Encourages Assertio Holdings, Inc. (ASRT) Investors to Inquire About a Securities Fraud Class ActionJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming DeadlineJanuary 26, 2024 | tmcnet.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) InvestorsJanuary 13, 2024 | stockhouse.comINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming DeadlineJanuary 12, 2024 | finance.yahoo.comEye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen ResearchJanuary 10, 2024 | finance.yahoo.comVaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen ResearchJanuary 9, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) InvestorsNovember 9, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRTJuly 24, 2023 | seekingalpha.comBuy Spectrum Pharmaceuticals For Exposure To Assertio HoldingsJuly 8, 2023 | fool.comSpectrum Pharmaceuticals (NASDAQ: SPPI)July 3, 2023 | benzinga.comMoore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law FirmJune 30, 2023 | finance.yahoo.comSPPI - Spectrum Pharmaceuticals, Inc.May 26, 2023 | msn.comHC Wainwright & Co. Reiterates Spectrum Pharmaceuticals (SPPI) Neutral RecommendationMay 17, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 15, 2023 | msn.comJefferies Downgrades Spectrum Pharmaceuticals (SPPI)May 14, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ForecastsMay 10, 2023 | finance.yahoo.comQ1 2023 Assertio Holdings Inc Earnings CallMay 9, 2023 | msn.comSpectrum Pharmaceuticals rises as co. says its Q1 net sales up 54% Q/QSee More Headlines Company Calendar Last Earnings11/10/2021Today5/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(617) 586-3900Fax702-260-7405Employees86Year Founded2002Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-263.04% Return on Equity-218.44% Return on Assets-66.16% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.38 Sales & Book Value Annual Sales$10.11 million Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book6.87Miscellaneous Outstanding Shares205,250,000Free Float199,704,000Market Cap$211.41 million OptionableOptionable Beta2.15 Social Links Key ExecutivesMr. Thomas J. Riga (Age 48)Pres, CEO & Director Comp: $1.07MMs. Nora E. Brennan (Age 54)Exec. VP & CFO Comp: $46.25kMr. Keith M. McGahan J.D. (Age 47)L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. Comp: $948.26kMr. Michael A. GrabowExec. VP & Chief Bus. OfficerDr. Lyndah K. Dreiling M.B.A.M.D., Sr. VP of Clinical Devel.Key CompetitorsRigel PharmaceuticalsNASDAQ:RIGLEmergent BioSolutionsNYSE:EBSRegulus TherapeuticsNASDAQ:RGLSXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsidersNora BrennanSold 32,387 sharesTotal: $35,625.70 ($1.10/share) SPPI Stock Analysis - Frequently Asked Questions How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.07. During the same period last year, the firm earned ($0.37) earnings per share. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). This page (NASDAQ:SPPI) was last updated on 5/25/2024 by MarketBeat.com Staff From Our PartnersThis could mean the end of the U.S dollar…Colonial MetalsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBiden FINISHED On June 13th?Paradigm PressJust $9 for a Year of Winning Market InsightsBehind the MarketsElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaNew Options need New Trading StrategiesNetpicks Adding Choose a watchlist: Watchlist My Default Watchlist Adding Spectrum Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.